系统性硬化症与临床显性心力衰竭发病风险的关联
这项基于台湾地区全民医保数据库的配对回顾性队列研究纳入1830例系统性硬化症(SSc)患者和27981例对照,发现SSc患者临床显性心力衰竭住院风险显著升高(校正HR 3.26,95%CI 2.49-4.28),且年龄<50岁患者风险更高(HR 7.8),提示SSc与临床显性心力衰竭相关,而非仅无症状性心室功能不全。
要点
- SSc患者心力衰竭住院风险较非SSc对照显著升高,校正HR 3.26(95%CI 2.49-4.28)。
- SSc患者3年、5年、10年心力衰竭住院累积发生率分别为3.5%、5.3%、9.7%。
- 年龄<50岁SSc患者的心力衰竭风险(HR 7.8)高于年龄≥50岁者(HR 2.78)。
核心结论
- SSc与临床显性心力衰竭风险显著升高相关,而非仅与无症状性心室功能不全相关。
研究设计与样本
- 匹配的回顾性队列研究,使用台湾地区全民保险数据库,纳入无心力衰竭病史的新发SSc患者,并按年龄、性别和队列进入时间匹配非SSc对照。
主要发现
- 共识别1830例SSc患者和27981例对照。
- SSc患者3年、5年、10年心力衰竭住院累积发生率分别为3.5%、5.3%、9.7%。
- 与非SSc个体相比,SSc患者心力衰竭风险升高,校正HR 3.26(95%CI 2.49-4.28)。
- 亚组分析显示,SSc对心力衰竭发生的影响在年龄<50岁患者中大于年龄≥50岁患者(HR 7.8 [95%CI 4.03-15.1] vs HR 2.78 [95%CI 2.06-3.76])。
临床怎么用
- 作者认为这些真实世界证据提示可使用适当的筛查策略,在SSc早期检出这些致死性并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Primary myocardial involvement is an important cause of death in systemic sclerosis (SSc). Subclinical diastolic/systolic heart dysfunction is recognized; however, whether this indicates a subsequent increased risk of clinically overt heart failure (HF) remains largely unknown. We aimed to investigate the risk of clinically overt HF in a large, unselected SSc cohort. METHODS: This matched, retrospective cohort study was conducted using a nationwide insurance database in Taiwan. Incident SSc patients with no history of HF were identified, and non-SSc comparison groups were selected and matched to the SSc groups by age, sex, and cohort entry time. The cumulative HF incidence was estimated using the Kaplan-Meier method. Multivariable Cox proportional hazards regression was used to calculate adjusted hazard ratios (HRs) for HF hospitalization. RESULTS: A total of 1,830 SSc patients and 27,981 controls were identified. The cumulative incidence of hospitalized HF at 3, 5, and 10 years among patients with SSc were 3.5%, 5.3%, and 9.7%, respectively. Compared with non-SSc individuals, SSc patients had an increased risk of HF (adjusted HR 3.26 [95% confidence interval (95% CI) 2.49-4.28]). Subgroup analyses revealed that the impact of SSc on the occurrence of HF was greater among patients ages <50 years than those ages ≥50 years (HR 7.8 [95% CI 4.03-15.1] versus HR 2.78 [95% CI 2.06-3.76]). CONCLUSION: SSc is associated with a markedly higher risk of clinically evident HF and not asymptomatic ventricular dysfunction alone. These findings provide real-world evidence suggesting the use of appropriate screening strategies to detect these lethal complications early in SSc.
引用
- Lin CY, Chen HA, Chang TW, et al. Association of Systemic Sclerosis With Incident Clinically Evident Heart Failure. Arthritis Care Res (Hoboken). 2023. PMID: 36071607. doi:10.1002/acr.25016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。